<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">Amniotic fluid cells are the possible source of stem cells for clinical purposes such as fetal therapies and regenerative medicine, where they proliferate rapidly can differentiate into different cells [
 <xref rid="bb0645" ref-type="bibr">129</xref>]. The human amniotic fluid is approved by US-FDA for tissue injury and also used to treat inflammatory and fibrotic diseases. The researchers from the University of Utah tested the nebulized and/or intravenous purified amniotic fluid in SARS-CoV-2 patients, where it reduced the respiratory inflammatory responses observed with this novel pandemic virus. Recently they received the approvals from regulatory bodies to perform the clinical trials (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04319731" id="ir0265" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04319731</ext-link>).
</p>
